This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Expanding upon the CRISPR-Cas9 geneediting system, researchers at MIT have designed a new technique called PASTE geneediting that can cut out defective genes and replace them with new genes in a safer and more efficient way. The PASTE geneediting technique was recently published in Nature Biotechnology.
In Nature Communications, Fred Hutch scientists demonstrate in a mouse model how genetherapy could cure an infection that afflicts billions of people Infectious disease researchers at Fred Hutchinson Cancer Research Center have used a geneediting approach to remove latent herpes simplex virus 1, or HSV-1, also known as oral herpes.
After spending almost an entire day deliberating the safety of Vertex Pharmaceuticals’ and CRISPR Therapeutics’ CRISPR-based genetherapy exa-cel for sickle cell disease, a US Food and Drug Administration (FDA) advisory panel appears to be satisfied with what it saw. CRISPR works as genetic scissors to edit parts of the genome.
The field of cell and genetherapies (CGT) is constantly evolving, and there has been significant progress in this area of research. However, despite the promise of these therapies, the regulations governing them lag the science, which in turn hinders the clinical translation of these novel medicines.
As of 2018, there were over 1,100 cancer therapies in development, and as of 2020, 362 of them were cell and genetherapies. Many novel therapies have been successfully developed through such partnerships.
CRISPR geneediting has transformed research, but it is not perfect, and can sometimes target unintended genes; to watch CRISPR enzymes respond to different genes, Leipzig University researchers developed a new method using DNA origami and were able to me Credit: Image courtesy of Julene Madariaga Marcos.
Innovations in Cancer Therapy CRISPR/Cas9, a groundbreaking gene-editing technology, has demonstrated significant potential in oncology, offering new avenues for cancer treatment. By editing these genes, researchers can effectively neutralize their cancer-promoting effects.
18, 2021 /PRNewswire/ — Aruvant Sciences, a private company focused on developing genetherapies for rare diseases, and Lonza announced today their agreement in support of ARU-1801, Aruvant’s one-time investigational genetherapy for sickle cell disease (SCD).
NEW YORK , Jan.
Vittoria Biotherapeutics is a clinical-stage cell therapy company that incorporates the latest advancements in cell therapy and geneediting with a unique approach that potentially overcomes some of the issues with this therapeutic modality. Its therapeutic pipeline targets unmet needs in oncology and autoimmune disease.
Moderna is aiming to build a geneediting franchise powered by some of the same technologies used in its COVID-19 vaccines. The Cambridge biotech company announced Wednesday that it will partner with Life Edit Therapeutics to develop potentially permanent treatments for rare genetic diseases and other conditions.
A man with muscular dystrophy who was first in line to receive an experimental geneeditingtherapy tailor made to treat the cause of his rare form of the disease has died. Terry had long been too old to participate in clinical trials of experimental therapies for the disease, which are often geared towards young boys.
Synthetic biology has grown exponentially in less than a decade, with CRISPR gene-editing as the key technology driving this through its use in areas like cancer, infectious diseases, and rare, undertreated indications. Here are my key takeaways from SynBioBeta’s conference. Alongside this, there is a need to take financial risks.
The epigenome plays a key role in many diseases such as heart disease, viral infections and cancer, and the new CRISPRoff technology could lead to powerful epigenetic therapies. In the paper, the scientists also describe the CRISPRon “antidote,” which removes methylation marks placed by CRISPRoff, making the process fully reversible.
The epigenome plays a key role in many diseases such as heart disease, viral infections and cancer, and the new CRISPRoff technology could lead to powerful epigenetic therapies. In the paper, the scientists also describe the CRISPRon “antidote,” which removes methylation marks placed by CRISPRoff, making the process fully reversible.
This research community is exploring diverse therapeutic avenues and creative thinking, including genetherapies, cell therapies, immunotherapies, novel drug candidates, and the repurposing of drugs from other indications.
DDL was founded in 1994, also originally started by a group of scientists operating in a university, also specialising in infectious diseases, but with more of a focus on HPV and Hepatitis. Viroclinics Biosciences – what it was called before the DDL purchase – was also well known for its specialist logistics infrastructure.
Meanwhile, BioMarin’s genetherapy Roctavian is approved by the FDA for the treatment of hemophilia A. Onureg (azacitidine), a leukemia therapy, also saw large growth of 70 percent to $124 million in 2022, and the multiple sclerosis drug Zeposia (ozanimod) generated $250 million in 2022, an 87 percent increase.
From rare disease drug approvals to treatments involving immunotherapies and genetherapies and awarding of a Nobel Prize to the inventors of the gene-editing tool CRISPR, 2020 was a year of great activity and productivity despite the backdrop of the pandemic. CRISPR GeneEditing Inventors Win Nobel Prize.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content